TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer

CAR-T Digest - August 2020

23 September 2025: TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer

TegMine Therapeutics entered a strategic R&D collaboration with Boehringer Ingelheim to advance its proprietary 2-Factor Antibody System for developing safer, more-specific ADCs
The partnership begins with one clinically validated cancer target, with potential expansion to two additional targets
TegMine’s platform identifies tumor-specific glycan epitopes and uses dual glycan/protein recognition to improve therapeutic precision and reduce off-tumor toxicity
TegMine will receive upfront payments, research funding per target, option fees for additional targets, and is eligible for milestone payments and royalties
Boehringer Ingelheim holds global development and commercialization rights for all targets generated under the collaboration